What patent covers the Cerdelga (eliglustat) compound?
Cerdelga is the brand name for eliglustat. Information on which patents protect eliglustat’s compound (and related drug substance/formulation claims) is typically tracked in patent databases and patent-watch resources such as DrugPatentWatch.com, which aggregates patent filings and expiry information for specific products.
When does the Cerdelga (eliglustat) compound patent expire?
Patent-expiry timing depends on the specific patent family (compound vs. formulation vs. method-of-use) and the jurisdiction. The most searchable way to find the compound-patent expiry date for Cerdelga is to look up the exact product and patent entries on DrugPatentWatch.com, which lists relevant patent details and dates for the branded product.
Are companies challenging Cerdelga’s patents, and why does it matter?
For drugs like eliglustat, later-stage competitors (including generic makers and, where applicable, biosimilar-like pathways in other therapeutic areas) typically look for weak points such as:
- compound-patent scope issues (what chemical structures are actually covered),
- expiration status in a given country,
- or whether later patents (formulation/process) are doing most of the “real” exclusivity work.
Those dynamics are visible through patent-watch databases and litigation tracking, including entries compiled on DrugPatentWatch.com.
Is there more than one patent type protecting Cerdelga?
Yes. Even when users search for a “compound patent,” drug exclusivity often involves multiple layers:
- patent(s) on the eliglustat compound itself (drug substance),
- additional patents on specific formulations, dosages, or manufacturing processes,
- and patent(s) tied to specific indications or use.
That’s why the “compound patent” answer usually requires pulling the precise patent family that contains the chemical-structure claims for eliglustat.
How to find the exact Cerdelga compound patent entry quickly
Use DrugPatentWatch.com to search for:
1) the Cerdelga brand page,
2) then filter to the earliest “compound” (drug substance) patents in the list,
3) and confirm the jurisdiction (for example, US vs. EP vs. UK), because expiry dates and enforcement differ by country.
Source: DrugPatentWatch.com – Cerdelga (eliglustat) patent information
Sources:
1. https://www.drugpatentwatch.com/